April 19, 2018 / 5:37 PM / 5 months ago

BRIEF-GW Pharma Announces Unanimous Positive Result Of FDA Advisory Committee Meeting

April 19 (Reuters) - GW Pharmaceuticals PLC:

* GW PHARMACEUTICALS AND U.S. SUBSIDIARY GREENWICH BIOSCIENCES ANNOUNCES THE UNANIMOUS POSITIVE RESULT OF FDA ADVISORY COMMITTEE MEETING FOR FIRST PLANT-BASED PHARMACEUTICAL CANNABIDIOL TREATMENT FOR SEIZURES IN PATIENTS WITH TWO RARE, SEVERE FORMS OF EPILEPSY

* GW PHARMACEUTICALS PLC - EPIDIOLEX WAS GENERALLY WELL TOLERATED WITH MOST ADVERSE EVENTS REPORTED AS MILD OR MODERATE

* GW PHARMACEUTICALS PLC - PDUFA GOAL DATE FOR COMPLETION OF NDA REVIEW OF THE CANNABIDIOL ORAL SOLUTION EPIDIOLEX IS JUNE 27, 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below